Symbols / REPL $8.54 +1.55% Replimune Group, Inc.

Healthcare • Biotechnology • United States • NMS
REPL Chart
About

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 705.17M
Enterprise Value 501.64M Income -314.85M Sales —
Book/sh 2.64 Cash/sh 3.26 Dividend Yield —
Payout 0.00% Employees 479 IPO —
P/E — Forward P/E -4.25 PEG —
P/S — P/B 3.23 P/C —
EV/EBITDA -1.57 EV/Sales — Quick Ratio 5.43
Current Ratio 5.60 Debt/Eq 36.26 LT Debt/Eq —
EPS (ttm) -3.44 EPS next Y -2.01 EPS Growth —
Revenue Growth — Earnings 2026-05-21 ROA -43.24%
ROE -90.88% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 82.57M
Shs Float 62.89M Short Float 35.23% Short Ratio 10.95
Short Interest — 52W High 13.24 52W Low 2.68
Beta 0.74 Avg Volume 1.52M Volume 3.22M
Target Price $12.86 Recom None Prev Close $8.41
Price $8.54 Change 1.55%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.86
Mean price target
2. Current target
$8.54
Latest analyst target
3. DCF / Fair value
$-37.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.54
Low
$10.00
High
$19.00
Mean
$12.86

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-05 main Piper Sandler Overweight → Overweight $14
2026-02-04 main Wedbush Outperform → Outperform $19
2025-11-03 up BMO Capital Underperform → Market Perform $11
2025-10-27 up HC Wainwright & Co. Neutral → Buy $12
2025-10-20 up JP Morgan Underweight → Neutral $11
2025-10-20 up Leerink Partners Market Perform → Outperform $13
2025-10-20 up Wedbush Neutral → Outperform $18
2025-09-19 down JP Morgan Neutral → Underweight —
2025-09-08 reit HC Wainwright & Co. Neutral → Neutral —
2025-07-30 up Cantor Fitzgerald Neutral → Overweight —
2025-07-23 down BMO Capital Outperform → Underperform $2
2025-07-23 down Barclays Overweight → Equal-Weight $3
2025-07-23 down HC Wainwright & Co. Buy → Neutral —
2025-07-22 down Leerink Partners Outperform → Market Perform $3
2025-07-22 down JP Morgan Overweight → Neutral $9
2025-07-22 main Jefferies Buy → Buy $6
2025-07-22 down Wedbush Outperform → Neutral $4
2025-07-16 main JP Morgan Overweight → Overweight $19
2025-07-03 reit HC Wainwright & Co. Buy → Buy $22
2025-06-20 init Cantor Fitzgerald — → Overweight —
News
RSS: Latest REPL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-18 ASTLEY-SPARKE PHILIP Director — 25,000 $0.00 $0
2025-12-19 HILL EMILY LUISA Chief Financial Officer — 60,000 $0.00 $0
2025-12-19 PATEL SUSHIL Chief Executive Officer — 200,000 $0.00 $0
2025-12-19 XYNOS KONSTANTINOS Officer — 60,000 $0.00 $0
2025-12-19 SCHWENDENMAN ANDREW Officer — 10,000 $0.00 $0
2025-12-19 SARCHI CHRISTOPHER Officer — 35,000 $0.00 $0
2025-12-09 DHINGRA KAPIL Director — 3,169 $10.40 $32,958
2025-12-09 DHINGRA KAPIL Director — 3,169 $1.75 $5,546
2025-12-02 PATEL SUSHIL Chief Executive Officer — 10,000 $11.13 $111,300
2025-11-17 XYNOS KONSTANTINOS Officer — 7,248 $9.10 $65,957
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
259.85
+11.60%
232.85
+33.70%
174.17
+51.26%
115.14
Research And Development
189.45
+8.28%
174.96
+38.28%
126.53
+59.06%
79.55
Selling General And Administration
72.18
+20.68%
59.81
+18.31%
50.55
+30.40%
38.77
Other Operating Expenses
-1.77
+7.66%
-1.92
+34.11%
-2.91
+8.08%
-3.17
Total Expenses
259.85
+11.60%
232.85
+33.70%
174.17
+51.26%
115.14
Operating Income
-259.85
-11.60%
-232.85
-33.70%
-174.17
-51.26%
-115.14
Total Operating Income As Reported
-261.63
-11.44%
-234.77
-32.58%
-177.08
-49.67%
-118.31
EBITDA
-235.43
-14.25%
-206.07
-23.11%
-167.39
-47.26%
-113.67
Normalized EBITDA
-256.55
-11.82%
-229.43
-29.33%
-177.40
-55.53%
-114.06
Reconciled Depreciation
3.50
+31.90%
2.65
+8.50%
2.45
+13.97%
2.15
EBIT
-238.94
-14.47%
-208.73
-22.90%
-169.84
-46.65%
-115.81
Total Unusual Items
21.12
-9.57%
23.36
+133.42%
10.01
+2465.64%
0.39
Total Unusual Items Excluding Goodwill
21.12
-9.57%
23.36
+133.42%
10.01
+2465.64%
0.39
Special Income Charges
—
—
—
0.00
Net Income
-247.30
-14.60%
-215.79
-23.82%
-174.28
-47.65%
-118.04
Pretax Income
-246.83
-14.60%
-215.39
-23.79%
-174.00
-47.41%
-118.04
Net Non Operating Interest Income Expense
-7.89
-18.51%
-6.66
-60.10%
-4.16
-87.13%
-2.22
Interest Expense Non Operating
7.89
+18.51%
6.66
+60.10%
4.16
+87.13%
2.22
Net Interest Income
-7.89
-18.51%
-6.66
-60.10%
-4.16
-87.13%
-2.22
Interest Expense
7.89
+18.51%
6.66
+60.10%
4.16
+87.13%
2.22
Other Income Expense
20.92
-13.30%
24.13
+457.21%
4.33
+747.23%
-0.67
Other Non Operating Income Expenses
-0.20
-126.20%
0.77
+113.58%
-5.68
-435.98%
-1.06
Gain On Sale Of Security
21.12
-9.57%
23.36
+133.42%
10.01
+2465.64%
0.39
Tax Provision
0.47
+14.71%
0.41
+41.67%
0.29
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+10400.00%
0.00
0.00
Tax Effect Of Unusual Items
4.44
-9.57%
4.90
+24409.09%
0.02
0.00
Net Income Including Noncontrolling Interests
-247.30
-14.60%
-215.79
-23.82%
-174.28
-47.65%
-118.04
Net Income From Continuing Operation Net Minority Interest
-247.30
-14.60%
-215.79
-23.82%
-174.28
-47.65%
-118.04
Net Income From Continuing And Discontinued Operation
-247.30
-14.60%
-215.79
-23.82%
-174.28
-47.65%
-118.04
Net Income Continuous Operations
-247.30
-14.60%
-215.79
-23.82%
-174.28
-47.65%
-118.04
Normalized Income
-263.98
-12.69%
-234.25
-27.12%
-184.27
-55.60%
-118.43
Net Income Common Stockholders
-247.30
-14.60%
-215.79
-23.82%
-174.28
-47.65%
-118.04
Diluted EPS
-3.07
+5.25%
-3.24
-8.36%
-2.99
-32.30%
-2.26
Basic EPS
-3.07
+5.25%
-3.24
-8.36%
-2.99
-32.30%
-2.26
Basic Average Shares
80.56
+21.02%
66.57
+14.36%
58.21
+11.49%
52.21
Diluted Average Shares
80.56
+21.02%
66.57
+14.36%
58.21
+11.49%
52.21
Diluted NI Availto Com Stockholders
-247.30
-14.60%
-215.79
-23.82%
-174.28
-47.65%
-118.04
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Assets
551.33
+13.04%
487.72
-24.57%
646.59
+40.20%
461.19
Current Assets
495.88
+14.35%
433.67
-26.82%
592.60
+46.69%
403.98
Cash Cash Equivalents And Short Term Investments
483.80
+15.01%
420.67
-27.89%
583.39
+47.45%
395.65
Cash And Cash Equivalents
111.12
+49.24%
74.46
-49.21%
146.59
+38.36%
105.95
Cash Equivalents
89.90
+118.73%
41.10
—
—
Cash Financial
21.22
-36.39%
33.36
—
—
Other Short Term Investments
372.69
+7.65%
346.21
-20.74%
436.80
+50.77%
289.71
Receivables
3.73
-24.32%
4.92
+67.47%
2.94
-3.80%
3.06
Other Receivables
3.73
-24.32%
4.92
+67.47%
2.94
-3.80%
3.06
Prepaid Assets
—
—
—
5.27
Other Current Assets
8.35
+3.39%
8.08
+28.66%
6.28
+19.19%
5.27
Total Non Current Assets
55.45
+2.58%
54.05
+0.12%
53.99
-5.64%
57.22
Net PPE
52.55
+0.36%
52.35
+0.01%
52.35
-5.81%
55.58
Gross PPE
65.94
+5.93%
62.25
+4.46%
59.59
-1.29%
60.37
Accumulated Depreciation
-13.40
-35.38%
-9.90
-36.66%
-7.24
-51.03%
-4.79
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
22.98
+32.27%
17.38
+42.06%
12.23
+18.48%
10.32
Construction In Progress
1.65
+47.72%
1.12
+42.66%
0.78
-51.64%
1.62
Other Properties
38.81
-7.32%
41.87
-6.69%
44.87
-5.82%
47.65
Leases
2.50
+32.77%
1.89
+10.55%
1.71
+117.32%
0.79
Other Non Current Assets
2.90
+70.76%
1.70
+3.91%
1.64
+0.00%
1.64
Total Liabilities Net Minority Interest
135.49
+19.67%
113.21
+24.00%
91.30
+82.73%
49.96
Current Liabilities
62.36
+54.22%
40.44
+19.55%
33.83
+62.96%
20.76
Payables And Accrued Expenses
32.23
+66.80%
19.32
+12.57%
17.16
+67.71%
10.23
Payables
12.46
+383.44%
2.58
-51.94%
5.36
+43.73%
3.73
Accounts Payable
12.46
+383.44%
2.58
-51.94%
5.36
+43.73%
3.73
Current Accrued Expenses
19.77
+18.05%
16.75
+41.89%
11.80
+81.47%
6.50
Pensionand Other Post Retirement Benefit Plans Current
20.08
+44.40%
13.91
+40.34%
9.91
+77.93%
5.57
Current Debt And Capital Lease Obligation
3.98
+2.68%
3.88
+3.25%
3.76
+3.44%
3.63
Current Capital Lease Obligation
3.98
+2.68%
3.88
+3.25%
3.76
+3.44%
3.63
Other Current Liabilities
6.07
+82.25%
3.33
+11.22%
2.99
+126.82%
1.32
Total Non Current Liabilities Net Minority Interest
73.12
+0.48%
72.78
+26.62%
57.47
+96.78%
29.21
Long Term Debt And Capital Lease Obligation
72.18
+0.27%
71.99
+26.29%
57.00
+95.17%
29.21
Long Term Debt
46.38
+3.50%
44.81
+56.41%
28.65
—
Long Term Capital Lease Obligation
25.80
-5.06%
27.18
-4.14%
28.35
-2.92%
29.21
Other Non Current Liabilities
0.94
+19.72%
0.79
+66.53%
0.47
—
Stockholders Equity
415.84
+11.04%
374.51
-32.56%
555.29
+35.03%
411.23
Common Stock Equity
415.84
+11.04%
374.51
-32.56%
555.29
+35.03%
411.23
Capital Stock
0.08
+26.23%
0.06
+7.02%
0.06
+21.28%
0.05
Common Stock
0.08
+26.23%
0.06
+7.02%
0.06
+21.28%
0.05
Share Issued
77.09
+25.51%
61.42
+8.36%
56.68
+19.73%
47.34
Ordinary Shares Number
77.09
+25.51%
61.42
+8.36%
56.68
+19.73%
47.34
Additional Paid In Capital
1,358.90
+26.90%
1,070.87
+3.47%
1,034.99
+43.08%
723.36
Retained Earnings
-948.58
-35.26%
-701.28
-44.45%
-485.49
-56.00%
-311.20
Gains Losses Not Affecting Retained Earnings
5.45
+12.21%
4.86
-15.26%
5.73
+688.80%
-0.97
Other Equity Adjustments
5.45
+12.21%
4.86
-15.26%
5.73
+688.80%
-0.97
Total Equity Gross Minority Interest
415.84
+11.04%
374.51
-32.56%
555.29
+35.03%
411.23
Total Capitalization
462.22
+10.23%
419.32
-28.19%
583.94
+42.00%
411.23
Working Capital
433.52
+10.25%
393.23
-29.63%
558.78
+45.81%
383.22
Invested Capital
462.22
+10.23%
419.32
-28.19%
583.94
+42.00%
411.23
Total Debt
76.17
+0.39%
75.87
+24.87%
60.76
+85.02%
32.84
Capital Lease Obligations
29.79
-4.10%
31.06
-3.27%
32.11
-2.22%
32.84
Net Tangible Assets
415.84
+11.04%
374.51
-32.56%
555.29
+35.03%
411.23
Tangible Book Value
415.84
+11.04%
374.51
-32.56%
555.29
+35.03%
411.23
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Cash Flow
-192.25
-3.66%
-185.47
-44.84%
-128.05
-55.82%
-82.18
Cash Flow From Continuing Operating Activities
-192.25
-3.66%
-185.47
-44.84%
-128.05
-55.82%
-82.18
Net Income From Continuing Operations
-247.30
-14.60%
-215.79
-23.82%
-174.28
-47.65%
-118.04
Depreciation Amortization Depletion
3.50
+31.90%
2.65
+8.50%
2.45
+13.97%
2.15
Depreciation And Amortization
3.50
+31.90%
2.65
+8.50%
2.45
+13.97%
2.15
Other Non Cash Items
4.68
+11.30%
4.20
+33.59%
3.15
+24.54%
2.53
Stock Based Compensation
35.04
+2.69%
34.12
+21.31%
28.13
+15.98%
24.25
Operating Gains Losses
-0.20
+73.93%
-0.77
-113.58%
5.68
—
Net Foreign Currency Exchange Gain Loss
-0.20
+73.93%
-0.77
-113.58%
5.68
0.00
Change In Working Capital
20.97
+759.43%
2.44
-80.43%
12.47
+164.89%
4.71
Change In Receivables
1.30
+168.01%
-1.92
-3040.98%
-0.06
+75.30%
-0.25
Change In Prepaid Assets
-0.25
+85.83%
-1.78
-67.89%
-1.06
-29.94%
-0.81
Change In Payables And Accrued Expense
21.68
+236.71%
6.44
-51.79%
13.36
+128.60%
5.84
Change In Accrued Expense
11.74
+27.17%
9.23
-18.83%
11.38
+140.76%
4.72
Change In Payable
9.94
+455.80%
-2.79
-241.04%
1.98
+77.19%
1.12
Change In Account Payable
9.94
+455.80%
-2.79
-241.04%
1.98
+77.19%
1.12
Change In Other Current Assets
-1.20
0.00
-100.00%
2.65
+4.99%
2.53
Change In Other Current Liabilities
-0.56
-84.64%
-0.31
-230.77%
0.23
+420.55%
-0.07
Investing Cash Flow
-23.80
-124.48%
97.20
+168.21%
-142.50
-7790.48%
-1.81
Cash Flow From Continuing Investing Activities
-23.80
-124.48%
97.20
+168.21%
-142.50
-7790.48%
-1.81
Net PPE Purchase And Sale
-6.69
-18.10%
-5.66
-149.43%
-2.27
+2.83%
-2.34
Purchase Of PPE
-6.69
-18.10%
-5.66
-149.43%
-2.27
+2.83%
-2.34
Capital Expenditure
-6.69
-18.10%
-5.66
-149.43%
-2.27
+2.83%
-2.34
Net Investment Purchase And Sale
-17.11
-116.63%
102.86
+173.35%
-140.23
-26558.87%
0.53
Purchase Of Investment
-403.59
+17.55%
-489.52
+16.09%
-583.41
-128.14%
-255.72
Sale Of Investment
386.48
-34.76%
592.38
+33.67%
443.18
+72.95%
256.25
Financing Cash Flow
252.40
+1450.06%
16.28
-94.77%
311.30
+4618.14%
6.60
Cash Flow From Continuing Financing Activities
252.40
+1450.06%
16.28
-94.77%
311.30
+4618.14%
6.60
Net Issuance Payments Of Debt
-0.60
-104.12%
14.52
-47.73%
27.79
+10626.14%
-0.26
Issuance Of Debt
0.00
-100.00%
15.00
-46.72%
28.15
0.00
Repayment Of Debt
-0.60
-25.84%
-0.48
-30.41%
-0.36
-38.26%
-0.26
Long Term Debt Issuance
0.00
-100.00%
15.00
-46.72%
28.15
0.00
Long Term Debt Payments
-0.60
-25.84%
-0.48
-30.41%
-0.36
-38.26%
-0.26
Net Long Term Debt Issuance
-0.60
-104.12%
14.52
-47.73%
27.79
+10626.14%
-0.26
Net Common Stock Issuance
155.73
0.00
-100.00%
187.29
0.00
Proceeds From Stock Option Exercised
97.27
+5429.68%
1.76
-98.17%
96.22
+1302.24%
6.86
Changes In Cash
36.35
+150.50%
-71.98
-276.64%
40.75
+152.66%
-77.39
Effect Of Exchange Rate Changes
0.32
+466.28%
-0.09
+21.10%
-0.11
-113.33%
0.82
Beginning Cash Position
76.16
-48.62%
148.23
+37.78%
107.58
-41.58%
184.15
End Cash Position
112.82
+48.14%
76.16
-48.62%
148.23
+37.78%
107.58
Free Cash Flow
-198.94
-4.09%
-191.13
-46.66%
-130.32
-54.20%
-84.52
Interest Paid Supplemental Data
4.20
+37.91%
3.04
+185.55%
1.07
0.00
Income Tax Paid Supplemental Data
0.10
-65.00%
0.30
0.00
-100.00%
0.06
Amortization Of Securities
-8.95
+27.41%
-12.33
-118.62%
-5.64
-353.96%
2.22
Common Stock Issuance
155.73
0.00
-100.00%
187.29
0.00
Issuance Of Capital Stock
155.73
0.00
-100.00%
187.29
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category